Are blood pressure medicines effective

The short version: blood pressure medicines reduce strokes, heart failure, and death in people with moderate-to-severe hypertension, but the benefit is smaller in mild cases and the evidence is dominated by industry-funded trials that compare one drug to another, not to doing nothing.

The evidence for treating high blood pressure is real but narrower than you are usually told. The SHEP trial, funded by the National Institutes of Health, found that treating people over 60 with chlorthalidone cut strokes by 36% and heart attacks by 27% [4]. The HYVET trial, also publicly funded, showed that treating people 80 and older with indapamide reduced all-cause mortality by 21% and heart failure by 64% [6]. A meta-analysis of older trials found that treatment roughly halved the risk of congestive heart failure (relative risk 0.48) and cut left ventricular hypertrophy by about a third [9]. These are real benefits, measured in hard outcomes, not surrogate endpoints.

But the picture gets murkier when you look at who paid for the research and what was compared. The CAPPP trial, funded by the manufacturer, compared captopril to older drugs and found no difference in overall heart attacks or death — the primary endpoint was essentially a tie [19]. The LIFE study, funded by Merck, compared losartan to atenolol and found fewer strokes with losartan, but both groups got blood pressure treatment; the question was which drug, not whether to treat at all [17]. The ACCORD trial in diabetics found that pushing blood pressure very low (119/64) reduced strokes but increased kidney problems and required 3.4 drugs per person versus 2.3 [22]. The benefit came at a cost.

The mechanism question matters here. High blood pressure damages small vessels in the brain, kidneys, and heart over years. The colloidal frame predicts that sustained pressure disrupts the glycocalyx and impairs zeta potential in the microcirculation, leading to sludging and end-organ damage. Lowering pressure mechanically reduces that shear stress. That is plausible and consistent with the trial data. What is less studied is whether non-drug approaches — diet, exercise, sodium restriction, stress reduction — achieve the same protection without the side effects. The evidence for lifestyle is strong but the trials are smaller and less profitable to run.

My call: for people with sustained systolic blood pressure above 150, the evidence supports treatment to prevent stroke, heart failure, and death. For mild hypertension (130-140), the benefit is smaller and the trade-offs with medication side effects are real. The evidence base is dominated by drug-vs-drug comparisons funded by manufacturers, not by long-term studies against no treatment. The burden of proof for starting medication in mild hypertension has not been fully met.

Confidence: moderate — the benefit at higher pressures is well-established in publicly funded trials, but the evidence for mild hypertension and the long-term safety of multi-drug regimens is thinner than the guidelines admit.